Genetic Technologies (GENE) Shares Gap Down to $1.05

Shares of Genetic Technologies Limited (NASDAQ:GENE) gapped down prior to trading on Wednesday . The stock had previously closed at $1.01, but opened at $1.05. Genetic Technologies shares last traded at $1.22, with a volume of 13155 shares changing hands.

Separately, ValuEngine downgraded shares of Genetic Technologies from a “buy” rating to a “hold” rating in a report on Monday.

A hedge fund recently bought a new stake in Genetic Technologies stock. Alpine Group USVI LLC acquired a new stake in Genetic Technologies Limited (NASDAQ:GENE) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 28,437 shares of the biotechnology company’s stock, valued at approximately $25,000. Genetic Technologies accounts for about 0.1% of Alpine Group USVI LLC’s investment portfolio, making the stock its 15th largest holding. Alpine Group USVI LLC owned approximately 0.18% of Genetic Technologies at the end of the most recent quarter. 3.87% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This news story was reported by Stock Observer and is the property of of Stock Observer. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.thestockobserver.com/2019/05/17/genetic-technologies-gene-shares-gap-down-to-1-05.html.

About Genetic Technologies (NASDAQ:GENE)

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.

Read More: What is the formula for the cash asset ratio?

Receive News & Ratings for Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.